⌘K
Loading ticker…
As of 2026-08-24, Atara Biotherapeutics, Inc (ATRA) has a 3-month relative strength percentile of 41 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 53. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 8.2%, relative volume 0.44×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
ATRA is held by 3 ETFs as of Apr 2026. Top owner: DCOR at 0.00% weight, $10K notional. Top 3 carry $15K.
Held by 6 ETFs · $1M across latest filings · largest weight 0.01% (IWC).
Top 3 by value, from SEC N-PORT-P filings dated Apr 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| DCOR | 0.00% | $10K | — |
| DFACDimensional U.S. Core Equity 2 ETF | 0.00% | $4K | — |
| DFASDimensional U.S. Small Cap ETF | 0.00% | $644 | new |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ATRA Jan avg: -7.09% median: -5.84% win: 50% σ: 56.06% n: 4 2022-04-12 → 2026-07-31 | ATRA Feb avg: -3.33% median: -7.94% win: 50% σ: 22.24% n: 4 2022-04-12 → 2026-07-31 | ATRA Mar avg: -16.49% median: -13.38% win: 0% σ: 8.05% n: 4 2022-04-12 → 2026-07-31 | ATRA Apr avg: 0.90% median: -0.58% win: 40% σ: 21.18% n: 5 2022-04-12 → 2026-07-31 | ATRA May avg: 7.49% median: -18.24% win: 20% σ: 64.78% n: 5 2022-04-12 → 2026-07-31 | ATRA Jun avg: 4.77% median: 5.23% win: 60% σ: 31.75% n: 5 2022-04-12 → 2026-07-31 | ATRA Jul avg: 2.81% median: 15.65% win: 60% σ: 46.04% n: 5 2022-04-12 → 2026-07-31 | ATRA Aug avg: -4.92% median: -9.04% win: 50% σ: 29.65% n: 4 2022-04-12 → 2026-07-31 (current) | ATRA Sep avg: 5.38% median: 4.17% win: 75% σ: 10.42% n: 4 2022-04-12 → 2026-07-31 | ATRA Oct avg: 5.92% median: 6.61% win: 75% σ: 14.97% n: 4 2022-04-12 → 2026-07-31 | ATRA Nov avg: -3.33% median: -0.55% win: 50% σ: 35.09% n: 4 2022-04-12 → 2026-07-31 | ATRA Dec avg: -5.19% median: -6.49% win: 50% σ: 23.31% n: 4 2022-04-12 → 2026-07-31 |